Biogen Inc. closed 41.53% short of its 52-week high of $238.00, which the company achieved on July 12th.

Let’s dig into the relative performance of Biogen (NASDAQ:BIIB) and its peers as we unravel the now-completed Q4 therapeutics ...

Biotechnology company Biogen (BIIB) announced on Monday plans for new headquarters at Kendall Common, located at 75 Broadway ...

We recently published a list of the 7 Most Undervalued Biotech Stocks To Invest In. In this article, we are going to take a ...

The company and Sanofi just posted positive results from a pivotal ADEPT Phase 2/3 trial. While we’re not seeing any specific news, BIIB has become a value play. Keep your portfolio well-protected ...

Biogen (BIIB) announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year ...

Commonwealth Equity Services LLC trimmed its holdings in shares of Biogen Inc. (NASDAQ:BIIB – Free Report) by 7.2% in the ...

Biogen believes that some of its new drugs, Leqembi, Skyclarys and Zurzuvae, have the potential to revive long-term growth. Can Biogen achieve this goal?

Bullish option flow detected in Biogen (BIIB) with 2,556 calls trading, 1.5x expected, and implied vol increasing over 1 point to 34.69%.